Pharmacogenetic studies indicated that the detoxifying activity of GSTs enzymes keeps safe cells from the adverse effects of xenobiotics, but may modify drug efficacy in cancer cells, resulting in drug resistance (Kassogue et al., 2014). The gene discussed is HPGDS; the disease is cancer.